metadata toggle
Pharmaceutical particulars
Closantel is rapidly absorbed into the systemic circulation after oral administration and peak plasma levels are attained at 24-48 hours after dosing. In plasma, closantel is bound more than 99 % to albumin. As a result, tissue distribution is very limited. On average, tissue levels are 15 times lower than plasma levels. The elimination half-life from plasma and tissues is 2 to 3 weeks in sheep and about 10 days in goats. Metabolism is negligible and the main excretion route is the bile. The urinary excretion is negligible.
Mebendazole is of low solubility and only slightly absorbed from the gastrointestinal tract. Consequently, mebendazole is eliminated almost unaltered via the faeces after oral administration of therapeutic doses. The slight fraction that is absorbed produces maximal plasma levels within 24 hours of administration. The absorbed fraction is metabolised by the liver. The metabolites are mainly eliminated via urine. Seven days after treatment, tissue levels of mebendazole are below the detection limit.
Incompatibilities
None known.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years
Special precautions for storage
Protect from light.
Keep container in outer carton.
Nature and composition of immediate packaging
1, 2.5, and 5 litre high-density polyethylene flexitainers with HDPE tamper evident caps and nozzles 9 and 10 litre high-density polyethylene jerrycans with white HDPE polyethylene cap with aluminium (triseal) insert or ureum cap with HDPE polyethylene insert.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Medicines should not be disposed of via wastewater.
DANGEROUS to aquatic life. Do not contaminate ponds, waterways or ditches with the product or empty container.
The veterinary medicinal product should not enter water courses as closantel may be dangerous for fish and other aquatic organisms.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.